Clinical trial
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving…
NCT00120705 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00120705 |
|---|---|
| Title | Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy |
| Official title | A Randomized, Open-Label, Pilot Study to Evaluate Every Three Week Maintenance Dosing of Darbepoetin Alfa Therapy in Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Anemia |
| Intervention type | Drug |
| Interventions | darbepoetin alfa |
| Enrollment | 204 |
| Start date | Nov 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Jul 19, 2005 |
| Last update posted | Mar 25, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: